1. Home
  2. KRYS vs NOVT Comparison

KRYS vs NOVT Comparison

Compare KRYS & NOVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • NOVT
  • Stock Information
  • Founded
  • KRYS 2015
  • NOVT 1968
  • Country
  • KRYS United States
  • NOVT United States
  • Employees
  • KRYS N/A
  • NOVT N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • NOVT Industrial Machinery/Components
  • Sector
  • KRYS Health Care
  • NOVT Miscellaneous
  • Exchange
  • KRYS Nasdaq
  • NOVT Nasdaq
  • Market Cap
  • KRYS 4.3B
  • NOVT 4.2B
  • IPO Year
  • KRYS 2017
  • NOVT N/A
  • Fundamental
  • Price
  • KRYS $155.71
  • NOVT $113.78
  • Analyst Decision
  • KRYS Strong Buy
  • NOVT Hold
  • Analyst Count
  • KRYS 9
  • NOVT 1
  • Target Price
  • KRYS $203.22
  • NOVT $133.00
  • AVG Volume (30 Days)
  • KRYS 295.3K
  • NOVT 326.9K
  • Earning Date
  • KRYS 11-03-2025
  • NOVT 11-04-2025
  • Dividend Yield
  • KRYS N/A
  • NOVT N/A
  • EPS Growth
  • KRYS 36.22
  • NOVT N/A
  • EPS
  • KRYS 4.91
  • NOVT 1.69
  • Revenue
  • KRYS $359,205,000.00
  • NOVT $956,880,000.00
  • Revenue This Year
  • KRYS $34.33
  • NOVT $5.06
  • Revenue Next Year
  • KRYS $47.84
  • NOVT $6.89
  • P/E Ratio
  • KRYS $31.68
  • NOVT $67.48
  • Revenue Growth
  • KRYS 116.08
  • NOVT 6.34
  • 52 Week Low
  • KRYS $122.80
  • NOVT $98.76
  • 52 Week High
  • KRYS $207.84
  • NOVT $184.11
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 60.39
  • NOVT 43.80
  • Support Level
  • KRYS $136.73
  • NOVT $113.34
  • Resistance Level
  • KRYS $152.96
  • NOVT $118.30
  • Average True Range (ATR)
  • KRYS 5.13
  • NOVT 2.86
  • MACD
  • KRYS 0.11
  • NOVT 0.11
  • Stochastic Oscillator
  • KRYS 97.23
  • NOVT 41.01

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About NOVT Novanta Inc.

Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.

Share on Social Networks: